SELLAS Life Sciences (SLS) announced before the opening bell on Tuesday, November 17, 2026, that its pivotal Phase 3 REGAL trial met its primary endpoint of overall survival. Per the company's press release, also filed with the SEC:

  • Hazard ratio: 0.59, a 41% reduction in the risk of death
  • Two-sided p-value: 0.035
  • Median overall survival: 24.0 months on galinpepimut-S (GPS) vs. 14.7 months on investigator's choice of best available treatment
  • Safety: no new safety signals; treatment-related adverse events were mostly grade 1 or 2, most often injection-site reactions
  • The company plans to meet with the FDA about an accelerated filing strategy and is preparing a Biologics License Application (BLA) submission for the first half of 2027. It also scheduled a webcast for 7:45 a.m. Eastern.

    We covered the setup on November 13, when SELLAS narrowed the readout to this month: SELLAS Puts a November Date on Its REGAL Readout.

    The +7% Headline Came Before the News Did

    Want to apply this to your own portfolio?Open OptionsPilot →

    Several outlets and posts described SLS as up about 7% premarket on the results. The timing doesn't support that. Cboe's halt list shows Nasdaq halted SLS at 6:55 a.m. Eastern with the reason "News pending," and a resumption quote time of 7:25 a.m. Yahoo Finance showed $8.00, up 7.10% from Monday's $7.47 close, but that print was stamped 6:54:58 a.m., before the halt and before the release crossed. Reuters later withdrew a 7:11 a.m. alert that said SLS was up 7%, because the stock was halted at the time (MarketScreener).

    Update, 6:20 AM PT: After trading resumed, SLS gapped far higher. StockAnalysis listed it at $27.10, up about 263%, on roughly 19.5 million premarket shares, and StockMarketWatch showed about $26.65, up about 257%, around 9:00 a.m. Eastern. Premarket prices are thin and can change quickly before the 9:30 a.m. open, and options don't trade until then.

    Our math, not a forecast: a print near $27 is more than double the roughly $11.60 upper break-even of the Nov 20 straddle discussed below, and it sits close to the Jan 15, 2027 $30 call strike, the large open-interest line in the table below. Short calls and the short side of put trades that looked far out of the money on Monday would be deep in the money at that price.

    A Small, Open-Label Trial With a p-Value Under 0.05

    The result cleared the bar, but the details are what analysts will pick apart on the webcast:

  • Size. REGAL randomized 126 patients 1:1, and the analysis was triggered at a pre-specified 80 deaths.
  • Design. The trial was open-label, so patients and investigators knew who got the vaccine.
  • Comparator. The control arm was investigator's choice: observation, a hypomethylating agent, venetoclax and/or low-dose cytarabine.
  • Margin. A two-sided p of 0.035 is significant against the conventional 0.05 threshold, but not by a wide margin.
  • What's still missing. SELLAS said full secondary-endpoint and pre-specified analyses are still underway and will be presented at a medical conference and in a journal.
  • None of that changes the topline result. It does explain why biotech traders often see a wide range of reactions to a "met primary endpoint" headline, and why the regulatory path (an accelerated filing, then an FDA review) still carries its own risk.

    A 55% Straddle and a 535 IV30 Going In

    Cboe's delayed quotes from Monday's close show how extreme the pricing was. The SLS Nov 20 $7.50 call was $1.90 / $2.20 and the $7.50 put was $1.90 / $2.20. That puts the at-the-money straddle at about $4.10 using midpoints, or roughly 55% of the $7.47 close, with break-evens near $3.40 and $11.60 by Friday. Near-the-money Nov 20 implied volatility was roughly 650% to 690%, and 30-day IV (IV30) was about 535, up from the roughly 336 we noted on November 13.

    Our math, not a forecast: that pricing means the event premium was huge. If implied volatility collapses once the stock reopens, long options can lose much of their extrinsic value even if the stock moves sharply. Short options, meanwhile, face the risk of a gap far beyond any strike, whichever way it goes.

    Puts Outnumbered Calls 3 to 1 Monday, but the Open Interest Leans the Other Way

    Monday's session showed a lot of downside hedging: about 96,900 puts against 29,200 calls traded. Standing open interest still leaned toward calls, at about 676,000 calls vs. 346,000 puts.

    | SLS contract | Monday volume | Open interest | Bid / Ask at close | Dec 18 $6 put~11,600~11,400$3.20 / $4.70 Dec 18 $2 put~11,300~10,800$0.05 / $1.80 Jan 15, 2027 $6 put~11,100~52,300$3.00 / $3.40 Dec 4 $6 put~11,000~10,800$2.75 / $4.00 | Jan 15, 2027 $30 call | ~6,600 | ~78,100 | $1.50 / $1.65 |

    The Dec 18 and Dec 4 $6 puts each traded about as many contracts as their open interest. That pattern suggests mostly new positions opened Monday, though volume alone doesn't show whether they were bought or sold. The Jan $30 calls, at four times Monday's close, are the chain's largest open-interest line in that table and represent long-dated upside bets or overwrites.

    Spreads Wide Enough to Drive a Truck Through

  • Bid-ask spreads. Several contracts above had spreads of a dollar or more on a $7 stock. Market orders on a reopening can fill far from fair value.
  • Halts can repeat. Volatile small caps can trigger limit-up/limit-down pauses after the open, freezing the stock while options quotes widen.
  • Dilution risk. Biotechs often raise capital after positive data. An offering can push the share price down even on good news. SELLAS hasn't announced one; this is a general pattern, not a prediction.
  • Assignment and early exercise. Deep in-the-money short options in a hard-to-borrow, high-volatility name carry real early-assignment risk.
  • Defined risk matters more here. Spreads cap the maximum loss, while naked short options in a name like this can lose many times the premium collected.
  • For background, see our implied volatility explainer and the OCC options disclosure document.

    Sources

  • SELLAS press release: Positive Pivotal Phase 3 REGAL Trial Data
  • SEC: SELLAS 8-K exhibit 99.1
  • Cboe: U.S. equities trading halts
  • Yahoo Finance: SLS quote and news
  • Reuters via MarketScreener: Incorrect alert on Sellas Life Sciences shares withdrawn
  • TipRanks / The Fly: Sellas reports REGAL trial meets primary endpoint
  • Cboe: SLS delayed options quotes
  • OCC: Characteristics and Risks of Standardized Options
  • *By the OptionsPilot Editorial Team. Published November 17, 2026, 5:15 AM PT; updated 6:20 AM PT. This article is for education only and is not investment advice. Options involve risk and are not suitable for all investors.*